Form 4: Capricor Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
A Capricor Therapeutics director, Paul Gisbert Auwaerter, acquired stock options for 19,130 shares on January 2, 2025, as part of his board service compensation.
Summary
- Paul Gisbert Auwaerter, a director at Capricor Therapeutics, acquired stock options for a total of 19,130 shares on January 2, 2025.
- These options are granted at an exercise price of $14.96 per share.
- The options are divided into three grants: 11,940 shares for annual board service, 1,440 shares for annual board committee service, and 5,750 shares for annual board service.
- The 11,940 share option vests monthly starting February 1, 2025, and ending December 31, 2025.
- The 1,440 and 5,750 share options are fully vested and exercisable immediately as of the grant date, January 2, 2025.
- The options expire on January 2, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard practice of director compensation, which is generally viewed positively as it aligns interests. There are no negative implications.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders.
- The vesting schedule for some options encourages continued service on the board.
Risks
- The early exercise feature of the options could lead to restricted stock if the director's service terminates before full vesting.
Industry Context
Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with shareholders and incentivizing performance.
Comparison to Industry Standards
- Stock option grants are a standard practice for compensating board members in the biotechnology industry, similar to companies like Amgen, Gilead Sciences, and Biogen.
- The vesting schedule of the options is also typical, with some options vesting over time to encourage continued service, while others are fully vested immediately.
Stakeholder Impact
- The stock option grants may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of the stock option grants and the date the fully vested options become exercisable. |
| 02/01/2025 | Start date for monthly vesting of 11,940 stock options. |
| 12/31/2025 | End date for monthly vesting of 11,940 stock options. |
| 01/02/2035 | Expiration date for all stock options. |
| 01/06/2025 | Date the Form 4 was signed. |
Keywords
stock options, Capricor Therapeutics, director, insider trading, equity compensation, board service, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.